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Background: Psychoses such as hallucinations are a frequent non-motor problem in patients with Parkinson
disease (PD) and serious psychosis requires anti-psychotic medications that worsen Parkinsonism. Although
psychosis could be associated with patient-related or biological factors such as cognition, age, and severity of PD,
it can also be associated with medications.
Therefore we aimed to investigate patient-related and medication-related risks of psychosis requiring anti-psychotic
medications (serious psychosis).
Methods: A retrospective cohort of 331 PD patients was followed for 2 years. Patient-related factors associated
with risk of psychosis were identified by a survival time analysis. In patients who developed psychosis,
medications during the hazard period (1-14 days before psychosis) were contrasted with those during the
control periods (1 and 3 months before psychosis) using a case–crossover analysis to identify medication-related
risks of psychosis.
Results: Serious psychosis was detected in 52 patients and the incidence was estimated to be 116
(95% confidence interval [CI], 85-148) per 1,000 person-years. Analyses of baseline characteristics revealed the
risk to be higher in patients with a modified Hoehn–Yahr stage of ≥4 (hazard ratio [HR], 2.22; 95% CI, 1.11-4.40),
those with a longer duration of PD (HR, 1.25; 95% CI, 1.00-1.55, per 5 years) and those with Mini-Mental State
Examination scores of ≤24 (HR, 2.66; 95% CI, 1.37-5.16). The case-crossover analysis revealed that anti-cholinergics use
(HR, 19.7; 95% CI, 2.39-162) elevated the risk, while donepezil use reduced it (HR, 0.48; 95% CI, 0.27-0.85).
Conclusions: Risk of psychosis was elevated by increasing severity of PD, cognitive dysfunction and duration of the
disease. It was elevated by use of anti-cholinergic drugs and reduced by use of donepezil. The medication-related risk
was higher in patients aged≥ 70 years. In contrast, there was no significant medication-related risk in younger patients,
suggesting different pathomechanisms between young and old patients.
Keywords: Dopa, Dopamine agonist, Anticholinergic, Case-crossover, Retrospective cohort study* Correspondence: sawada@unh.hosp.go.jp
1Clinical Research Center, 8 Ondoyamacho, Narutaki, Ukyoku Kyoto 616-8255,
Japan
2Department of Neurology, National Regional Center for Neurological
Disorders and Utano National Hospital, 8 Ondoyamacho, Narutaki, Ukyoku
Kyoto 616-8255, Japan
Full list of author information is available at the end of the article
© 2013 Sawada et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Sawada et al. BMC Neurology 2013, 13:145 Page 2 of 8
http://www.biomedcentral.com/1471-2377/13/145Background
Psychosis is often seen in the disease course of Parkinson
disease (PD) patients receiving long-term treatment, even
in those without dementia [1]. It varies from mild and
transient hallucinations such as “passage hallucination” to
sustained delusions [2,3]. The prevalence, including mild
psychosis with preserved insight, is ~40-60% [2], so psych-
osis is one of the most prevalent and important non-motor
complications. Although mild, simple visual hallucinations
with retained insight do not require additional medical
treatment, severe psychosis requires hospitalization
and is associated with mortality [4]. Although visual
hallucinations are associated with PD brain pathology [5],
they could be associated with dopaminergic replacement
therapy [6], especially that involving dopamine agonists
[7-9]. Antipsychotic drugs except for clozapine [10]
improve psychosis insufficiently [11,12], but worsen
motor symptoms [13]. Therefore, finding out a way to
prevent psychosis during treatment for PD is important.
Although there is no association between hallucinations
and dopamine receptor genotype or apolipoprotein ε geno-
type [14], patient-specific factors may be involved because
psychosis often reoccurs in some patients and seldom oc-
curs in others [15]. Psychosis is associated with cognitive
dysfunction [15-17], which is related to non-dopaminergic
neuronal degeneration [18]. Psychosis could be a compos-
ite phenomenon of patient-related or biological factors
such as cognition, age, severity of PD and “trigger medica-
tions”. The purpose of the present study was to investigate
the incidence of psychosis and evaluate patient-related
and medication-related risk factors. To identify what
medications could trigger psychosis we adopted a case-
crossover design that enabled us to study the effects of
transient triggers on the risk of acute events, such as
psychosis [19].Methods
Study design
We conducted a retrospective cohort study to investi-
gate the associations between patient-related factors
and psychosis, and then analyzed the risk associated
with different medications. First, a survival time ana-
lysis was adopted to identify patient-related factors.
Then, with adjustment for these factors, a case-crossover
design study (self-matched comparison that compared
hazard and control periods in each patient with psychosis)
was performed to evaluate the risk associated with
medications.
This study was approved by the Bioethics Committee
of Utano National Hospital (No.18-16). According to the
Bioethics Committee, informed patient consent was not
needed because the study was a retrospective review and
data were analyzed anonymously.Patients
The medical records of consecutive patients with PD
who were treated in the Department of Neurology, the
National Regional Center for Neurological Disorders and
Utano National Hospital from March 2004 to November
2007 were retrospectively reviewed over a period of two
years. Inclusion criteria were as follows. Patients who were
diagnosed with Parkinson disease according to the United
Kingdom Parkinson’s disease Brain Bank Diagnostic
Criteria (step 1 and 2) [20], and who were prescribed
dopaminergic replacement therapy. Irrespective of age,
sex and severity of PD, both outpatients and hospitalized
patients were included. Patients with a past history of
psychosis were also included. Exclusion criteria were as
follows; patients prescribed anti-psychotic drugs during
the preceding 1 month; patients with a history of schizo-
phrenia; and patients who met the DLB consensus criteria
for probable or possible dementia with Lewy bodies [21].
Definition of psychosis
The primary study outcome was serious psychoses, defined
as those requiring a prescription of anti-psychotic drugs.
According to the guidelines of PD psychosis, we assumed
that prescription of anti-psychotic drugs was justified
principally when psychosis was not improved by other
treatments [22,23] and patient suffering and behavioral
changes were severe enough to endanger the patients or
others. The diagnosis of psychosis was made based on the
presence of psychotic symptoms (illusions, false sense of
presence, hallucinations, or delusions) that were recurrent
or prolonged for ≥1 month according to the provisional
diagnostic criteria for PD psychosis [24]. Anti-psychotic
drugs included all anti-psychotic drugs available in
Japan; tiapride, sulpiride, risperidone, chlorpromazine,
thioridazine, fluphenazine, propericiazine, levomepromazine,
haloperidol, quetiapine, olanzapine, perospirone, and
aripiprazole. Prescriptions were collected longitudinally
from study enrollment to the endpoint, which was defined
as the occurrence of psychosis that required anti-psychotic
drugs or the end of the 730 days of the study period.
Survival time analysis
In a survival time analysis, the observation period, censor-
ing, and endpoint were defined as follows. The observation
period was from the time of study enrollment to the
endpoint, which was defined as the occurrence of any
psychosis that required anti-psychotic drugs or the end
of the 730-day study period. Observation was censored if
patients were lost to follow-up or experienced an alternative
outcome. Patients were censored when they were trans-
ferred to other hospitals because data could not be
obtained (lost to follow-up). Because anti-psychotic medica-
tions were often prescribed prophylactically by surgeons to
avoid surgery-associated delirium, patients who underwent
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outcome).
In patients with motor fluctuations modified Hoehn-Yahr
(mH-Y) stage was evaluated in “ON period.” Although age
and duration of PD increased during the study period, and
mH–Y stage and Mini-Mental State Examination (MMSE)
scores might deteriorate, these variables were collected at
the time of enrollment on the assumption that changes in
them would not have much influence on the results of the
survival time analysis.
Case-crossover analysis
For the case-crossover analysis, the prescriptions in the
hazard period and those in the control periods were
compared. Medications were prescribed every 14 days or
28 days in most cases, and drugs that were taken 1 day
before the endpoint (the start of anti-psychotic medica-
tions) had been taken for 14 or 28 days before the endpoint;
therefore, medications taken 1 day before the endpoint
represent those taken for 14 days before the endpoint. In
this context, the prescription 1 day before the endpoint
was regarded as that in the hazard period. Medications in
the hazard period were compared with those in the con-
trol periods (30 and 90 days before psychosis) (Additional
file 1: Figure S1).
Prescription information was collected consecutively
because it was changeable weekly or monthly. All prescrip-
tions were collected to investigate the prescription of
antipsychotic drugs throughout the observation period
(of up to 2 years). Patients who had never been prescribed
antipsychotic drugs within the observation period were
regarded as controls or censored. In cases where anti-
psychotic drugs were prescribed, the reason why the anti-
psychotic drugs were prescribed was confirmed based on
medical records.
To identify trigger medications, the doses of dopa-
minergic agents including L-Dopa, entacapone, dopa-
mine agonists, amantadine and selegiline were collected.
L-Dopa dose was calculated using the following formula:
1.0 × regular levodopa dose or 1.25 × regular levodopa
dose if taking entacapone. Dopamine agonist dose was
calculated as the L-Dopa equivalent dose (LDED) according
to the following formula [17,25]:
LDED mgð Þ ¼ pramipexole mgð Þ  67þ ropinirole mgð Þ
 25þ pergolide μgð Þ  67þ cabergoline mgð Þ
 67þ bromocriptine mgð Þ  10
þ talipexole mgð Þ  67
Because psychosis could be related to anticholinergic
drugs, records of prescription of central anticholiner-
gic drugs (trihexyphenidyl, piroheptine, biperiden, and
promethazine) and that of donepezil (a central cholin-
ergic drug) were collected. Records of prescription ofrivastigmine were not collected because this drug was
unavailable in Japan during the study period.
Statistical analysis
The incidence of psychosis was estimated as the number
of patients with psychosis divided by the corresponding
person-years at risk. The survival time was defined as
the duration from enrollment to the first occurrence of
psychosis. The risk of psychosis owing to patient-related
factors was estimated using the Cox proportional hazard
model incorporating age, sex, duration of PD, mH–Y stage
(1.0-3.0 versus 4-5), and MMSE scores (≤ 24 versus > 24)
at study enrollment as predictable variables. Age and sex
were entered into the model and the other factors were
selected according to a backward stepwise likelihood ratio
test (Analysis I). Considering the patient-related factors
identified in Analysis I, medications were analyzed in a
case-crossover study design. Doses of L-Dopa, dopamine
agonists, amantadine, and selegiline, as well as the use of
anticholinergic drugs, were analyzed. Donepezil hydro-
chloride, an inhibitor of brain acetylcholine esterase, was
also included in the analysis. The relative risk was then
estimated using a generalized estimating equation that is
the most appropriate technique for case-crossover designs
[26-28]. Link function was logistic and an autoregressive
working correlation matrix was adopted because the data
were collected longitudinally and it was assumed that the
correlation of medication dose depends on the intervals
between data collection time points. A variance-covariance
matrix was estimated using the Huber-White sandwich
estimator. All two-way interactions between predictable
factors or covariates were examined and interactions were
considered and they were incorporated in the analysis if
statistically significant (Analysis II). Because risk of
psychosis owing to medications may be enhanced in
elderly patients, the case-crossover analysis was also
performed in the subgroup of patients aged ≥ 70 years.
P values of less than 0.05 were considered statistically
significant. Statistical analyses were performed using the
statistical software program IBM SPSS version 21.
Variables
In the multiple variable analysis patients with missing
variables were excluded. Dose of L-Dopa with adjustment
for entacapone and dopamine agonists, selegiline and
amantadine were regarded as scale variables. Anticholiner-
gic drugs and donepezil hydrochloride were regarded as
dichotomous (use versus no use).
Study size
On the basis of previous reports, incidence of psychosis
was estimated 80 per 1,000 person-years 18]. The sample
size was calculated to be 375 because 60 psychosis events
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logistic analysis of six kinds of medications).
Results
Among 417 patients with PD, 86 patients were excluded
because of use of antipsychotic drugs at study enrollment;
therefore, 331 patients were evaluated.
Analysis I
One-hundred and ninety-two patients were followed
until the occurrence of serious psychosis or the end of the
study, and all prescriptions were collected longitudinally.
During the study period 139 patients were censored
because they were transferred to local hospitals (n = 128)
or underwent surgery (n = 11). Fifty-two patients required
anti-psychotic medications against psychosis (33 with
visual hallucinations, 3 with auditory hallucinations, 1 with
somatosensory hallucinations, and 15 with delusions). The
assumption that anti-psychotic drugs were prescribed
when psychotic symptoms were not improved by other
treatments and the patients suffered was confirmed. No
patients were prescribed anti-psychotic drugs for delir-
ium. Two-hundred and seventy-nine patients (including
the 139 that were censored) did not require them during
the 2-year period (Figure 1). The incidence of psychosis
was 116 (95% confidence interval [CI], 85-148) per 1,000
person-years.
Characteristics of patients with and without psychosis
are summarized in Table 1. Sex, mH–Y stage, MMSE score





in a survival time analysis
139 excluded for Analysis II
(censored)
Analysis II (n=52*)
Intra-subject  comparison of 
medication in patients who 
developed psychosis
(case-crossover)
140 excluded for Analysis II
(without psychosis)
Figure 1 Flow diagram of patients included in and excluded
from the study. The numbers of patients included and excluded in
the analyses. The study involved Analysis I (patient-related factor in
a survival time analysis and Analysis II (intra-subject comparison of
medication). *According to the purpose of analyses, all participants
were included in Analysis I, and participants without psychosis
were excluded from Analysis II.patients with psychosis and those without psychosis.
Kaplan–Meier curves for the cumulative incidence of
psychosis according to mH–Y stage (1-3 or 4-5), and
MMSE score (≤24 or >24) are shown in Figure 2.
Within the 2 years, >35% of the patients with an MMSE
score ≤24 experienced psychosis, whereas only ~10% of
the patients with an MMSE score >24 succumbed. More
than 30% of the patients with a mH–Y stage of 4-5 de-
veloped psychosis during the study period, whereas
only ~10% of the patients with a mH–Y stage of 1-3
developed psychosis. Cox hazard models demonstrated
that duration of PD, mH–Y stage and MMSE score were
statistically significant risk factors with age-and sex-
adjusted hazard ratios (HRs) of 1.43 (95% CI, 1.17-1.73)
(per 5 years), 3.39 (95% CI, 1.88-6.11) (4-5 versus 1-3), and
3.60 (95% CI, 1.90-6.84) (≤ 24 versus > 24), respectively.
The multivariable-adjusted HRs were 1.25 (95% CI,
1.00-1.55), 2.22 (95% CI, 1.11-4.40) and 2.66 (95% CI,
1.37-5.16), respectively.
Analysis II
The correlation of medication doses among data collec-
tion time points depends on the length of the intervals
(Additional file 2: Figure S2). Therefore a generalized
estimating equation was adopted with an autoregressive
matrix. Incorporating medications as predictable variables,
the risk owing to drugs was analyzed in patients with
psychosis adjusting for age, sex, duration of PD, mH–Y
stage, and MMSE score. Because the interactions between
anticholinergic drugs and duration of PD (HR 0.76, 95% CI,
0.64-0.89, p = 0.001), were highly significant, the interaction
was also incorporated into the equation. There were no
other significant interactions between factors. The HR for
the use of anticholinergic drugs was 19.7 (95% CI, 2.39-163;
p = 0.006). Donepezil was negatively associated with psych-
osis (HR 0.48; 95% CI, 0.27-0.85; p = 0.012) (Table 2). In the
subgroup analysis of patients aged ≥70 years, use of anti-
cholinergic drugs was positively associated with psychosis
(HR 188, 95% CI, 13.9-2551, P < 0.001). Donepezil was
again negatively associated with psychosis (HR 0.28, 95%
CI, 0.08-1.01), and the association was statistically marginal
but not significant (p = 0.051). In addition the dose of
dopamine agonists was significantly associated with
psychosis (HR 1.65, 95% CI, 1.02-2.66, p = 0.035). The
interaction between anti-cholinergic drugs and PD duration
was also significant (HR 0.62, 95% CI 0.50-0.77, p < 0.001).
In contrast there were no significant associations between
medications and psychosis in the subgroup of patients
aged <70 years.
Discussion
In this study, psychosis developed in 52 patients and was
associated with disease severity, cognitive dysfunction, and
longer disease duration. Furthermore, the occurrence of
Table 1 Baseline characteristics by occurrence of psychosis
Psychosis (+) Psychosis (−) Censored P
value***Characteristics (n = 52) (n = 140) (n = 139)
Male, n (%) 27(51.9) 47(33.6) 68(48.9) 0.02
Age (Y), mean (SD) 70.7(6.9) 68.9(9.0) 69.4(10.2) 0.14
mH-Y stage*, n (%) 1-3 20(39.2) 107(76.4) 72(56.7) <0.0001
4-5 31(60.8) 33(23.6) 55(43.3)
MMSE** Mean (SD) 21.8(5.1) 25.6(4.2) 24.3(5.3) <0.0001
≤24 , n (%) 32(68.1) 37(29.8) 47(44.8) <0.0001
>24, n (%) 15(31.9) 87(70.2) 58(55.2)
Age of PD onset, mean (SD) 60.5(9.9) 61.7(10.9) 61.8(12.2) 0.51
Duration (Y), mean (SD) 10.2(7.0) 7.3(5.3) 7.2(5.3) 0.002
Abbreviations: n, number; Y, years; SD, standard deviation; mH-Y, modified Hoehn-Yahr stage; MMSE, Mini-Mental State Examination; PD, Parkinson’s disease.
*, ** the variable totals not equal to total numbers due to missing values.
*n = 51 (psychosis (+)), 140 (psychosis (−)), 127 (censored).
**n = 47 (psychosis (+)), 124 (psychosis (−)), 105 (censored).
***comparison between pychosis (+) and psychosis (−).
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drugs, suggesting that cholinergic neuronal degeneration
could be associated with the occurrence of psychosis.
Although anti-psychotic drugs are contraindicated in
PD patients, guidelines suggest that they could be used to
treat psychosis when it is not improved by other treatments
[22,23]. In this study, prescription of anti-psychotic drugs
in such patients was justified by the reason described above.
Antipsychotic drugs might also be used against agitation
or aggression. However, in this study, no patients were
agitated or aggressive without having delusions or hallu-
cinations. If the occurrence of psychosis is defined solely
on the basis of the use of anti-psychotic agents, mild
psychosis could be overlooked. However, such a defin-
ition is a suitable method because the purpose of the
study was to determine how to avoid serious psychosis
requiring anti-psychotic medications. In a prospective
population-based study, the incidence of psychosis wasCognitive function
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Figure 2 Kaplan-Meier curves of psychosis by the severity of PD and
Mini-Mental State Examination. A. Patients with MMSE scores >24 (n = 162)
exclusion of 56 patients because of missing values. B. Patients with a mH-Y
were compared after exclusion of 13 patients because of missing values.reported to be 79.7 per 1,000 person-years [17]. In the
present study, it was estimated to be 116 per 1,000
person-years. This was higher than the incidence in the
previous report because of several reasons. This figure
included recurrence of psychosis in patients with a his-
tory of psychosis and clinic-based incidence, and anti-
cholinergic drugs were used frequently. In the present
study, the maximal length of the observation period was
two years. Therefore, several factors such as cognitive
function and PD severity could deteriorate during the
observation period. In the survival analysis, patient-related
factors were assumed to be stable because of limitations of
the statistical methods. Psychosis is caused by multiple
factors including patient-related factors and trigger medi-
cations, and there is no way to clearly differentiate psych-
osis due to drugs from that due to other conditions.
Although these issues are limitations of the study, the
results demonstrated that the severity of PD, cognitiveSeverity of Parkinson disease
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by cognitive function. mH–Y; modified Hoehn–Yahr stage, MMSE;
and those with MMSE scores ≤24 (n = 116) were compared after
stage of 1-3 (n = 201) and those with a mH-Y stage of 4-5 (n = 120)
Table 2 Psychosis risk by medications (intrasubject comparison)








Drugs L-Dopa Per 100 mg /day 0.92(0.79-1.07) 0.27 1.06(0.85-1.32) 0.59 0.82(0.67-1.00) 0.05
DA agonists Per 100 mg(LDED) /day 1.25(0.88-1.77) 0.20 0.85(0.51-1.42) 0.53 1.65(1.02-2.66) 0.035
Amantadine Per 50 mg /day 0.87(0.75-1.02) 0.08 0.76(0.55-1.05) 0.09 0.86(0.63-1.17) 0.33
Selegiline Per 2.5 mg /day 1.06(0.85-1.33) 0.590 0.88(0.64-1.21) 0.42 1.24(0.76-2.01) 0.39
Anti-cholinergics Use 19.7(2.39-163) 0.006 0.80(0.38-1.68) 0.55 188.4(13.91-2551) <0.0001
Not use (Ref) 1 1 1
Donepezil use Use 0.48(0.27-0.85) 0.012 0.79(0.51-1.22) 0.29 0.28(0.08-1.01) 0.051
Not use (Ref) 1 1 1
Interaction Anti-cholinergics X duration 0.76 (0.64-0.89) 0.001 0.62(0.50-0.77) <0.0001
Dopa were expressed as adjusted values including concomitant entacapone.
*HR was adjusted for age, sex, mH-Y (1-3 vs 4-5), MMSE (= < 24 vs >24) and duration of PD, using a generalized estimating equation.
HR was calculated for Dopa (100 mg/d, adjusted), DA agonist (LDED, 100 mg/d), selegiline (2.5 mg/d), amantadine (50 mg/d), anti-cholinergics (use vs not use),
and donepezil (use vs not use).
Hazard period: prescription at psychosis occurrence.
Control period: prescription 1 month and 3 months before psychosis occurrence.
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cant risk factors for psychosis. This result is consistent
with those of previous studies [5,15-17,25]. In addition,
sleep disturbances [25,29] and rapid eye movement
(REM)-sleep behavioral disturbances [17] are associated
with psychosis. Arousal systems, including nor-adrenaline
neurons in the locus coeruleus, serotonin neurons in the
raphe nuclei, and cholinergic neurons in the basal forebrain
are damaged in PD [18,30]. Taken together, this informa-
tion suggests that psychosis may be related to degeneration
of cholinergic or serotonergic neurons. The use of anti-
cholinergic drugs elevated the risk of psychosis and the
use of donepezil reduced the risk, based on the results of
Analysis II. This result is consistent with a previous
report showing that rivastigmine, another acetylcholine
esterase inhibitor, improves psychosis in PD [31] and these
data suggest that psychosis is caused mainly by degener-
ation of cholinergic neurons in the brain arousal system.
The function of brain cholinergic neurons is more severely
affected in PD than in Alzheimer’s disease [32] and is
impaired even in early stage of PD [33]. There was a
significant interaction between PD duration and the use
of anti-cholinergics because anti-cholinergics were pre-
viously used more frequently, and so were prescribed
to patients with longer PD durations (data not shown).
Although the mechanisms by which impairment of cho-
linergic neurons leads to psychosis are still unclear, the
possibility that impairment of the inhibitory cholinergic
circuit in the cerebral motor cortex is associated with
visual hallucinations has been proposed [34]. Although
psychosis might also be associated with sleep disorders,
concomitant diseases, drugs other than those used in PD,
hospitalization, or ocular disorders, these factors were not
investigated in the present study.Although no association between dopamine agonists
and psychosis was identified in Analysis II, the risk posed
by dopamine agonists was identified as being significant in
the subgroup analysis of elderly patients. Relative risk of
psychosis owing to dopamine agonists was 1.65 (1.02-2.66)
per 100 mg (LDED) /day in patients aged ≥ 70 years, but it
was not significant in patients aged <70 years. To clarify
the risk owing to dopamine agonists in elderly patients,
dose at the time of study enrollment in patients stratified
by age (<70 versus ≥70) was examined. There was no
significant difference in these doses between patients with
psychosis and those without psychosis (Additional file 3:
Table S1). These data show that dose escalation of dopa-
minergic drugs is a significant trigger in elderly patients
but not in the entire cohort of patients, suggesting that
dopamine agonists elevated the risk in psychosis-prone
elderly patients but not in low-risk younger patients.
In this context, psychosis could be avoided by careful
application of dopamine replacement therapy in elderly
or high-risk patients.
Because mild psychosis is not detected if patients or
their caregivers do not complain of it, it is important how
to define the occurrence of psychosis. In this study, the
endpoint was defined as prescription of anti-psychotics.
Neurologists intend to avoid prescribing anti-psychotics in
patients with PD; therefore, the definition is a hard end-
point that has clinical significance. The participants in this
study included patients with advanced disease and a history
of psychosis. Therefore, the assessment of risk owing to
medications estimated in this study cannot be extended to
subjects with early-stage disease. In addition, it has not
been elucidated whether there is a dose threshold for
dopamine agonists to cause psychosis. To resolve these
issues further examinations are required.
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The present study showed that psychosis is associated
with the severity and duration of PD, and that patients with
cognitive decline are prone to psychosis. After adjustment
for these factors, anticholinergic drugs elevated the risk of
psychosis, and in psychosis-prone elderly patients, dose
escalation of dopamine agonists also elevated the risk.
Additional files
Additional file 1: Figure S1. Schematic demonstration of hazard and
control periods. The red period represents the hazard period, in other
words, the period with trigger medications. Medications were prescribed
every 14 or 28 days; therefore, the duration of the hazard period was
14─28 days. Drugs taken in the hazard period were not changed in the
period. Therefore, drugs that were taken 1 day before the endpoint
(red arrow) represent the drugs prescribed in the hazard period. Similarly
drugs that were taken 30 days or 90 days before the endpoint
(blue period) represent drugs prescribed in the two control periods
(blue arrows).
Additional file 2: Figure S2. Correlation of medication doses at various
time points (1, 30, and 90 days before the occurrence of psychosis). To
confirm the assumption that the correlation of medication dose depends
on the intervals between data collecting time points, doses of L-Dopa
(A), dopamine agonists (B), selegiline (C), and amantadine (D) were
plotted between 1, 30, and 90 days before the occurrence of psychosis.
There were correlations between time points, and the correlation
depended on the intervals between data collection time points.
Therefore, data were analyzed using an autoregressive working
correlation matrix as described in the Methods.
Additional file 3: Table S1. Baseline dose of dopamine agonists
(LDED mg/day) of patients who developed serious psychosis and those
who did not, stratified by age.
Abbreviations
PD: Parkinson disease; CI: Confidence interval; HR: Hazard ratio;
mH-Y: Modified Hoehn-Yahr; MMSE: Mini-Mental State Examination; LDED:
L-Dopa equivalent dose.
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